This article was written for Clinical Pathways Magazine
Determining how to pay for the treatment of uncommon yet serious diseases is an important consideration in terms of sustainability and patient access.
Novel and expensive therapies will create financial pressure for payers’ drug budgets. Clinical pathways have demonstrated success at determining the “right treatment for the right patient at the right time,” but they also have the potential to be used to provide guidance on the “right” payment path or alternative payment models to ensure access and to decrease financial burdens for patients and strain on payers and providers.
Medical Associate, Government Policy Systems, Managed Markets
Matthew supports clinical services and leads clinical content for Government Policy Systems (GPS). He facilitates discussions with EVERSANA’s bench of payer consultants and manages government policy content including topics impacting healthcare delivery systems. He has held a variety of roles in biopharma, some of which include landscape analyses in oncology, advisory boards for respiratory and […]
DO, MGH, MBA, AGSF, CMD, Chief Medical Director, Managed Markets
Richard has focused his career on improving health outcomes, especially for some of the most vulnerable populations. This has been achieved through several avenues, beginning with his continued active role as a treating internist/geriatrician. He has also put this focus into practice as chief medical officer for several management care plans, including ElderHealth/Bravo/HealthSpring/Cigna and PACE […]